Dark

Check out our Level2View

CYCC
Cyclacel Pharmaceuticals, Inc
stock NASDAQ

Inactive

Sep 11, 2025

6.37USD-5.982%(-0.40)220,498

Pre-market

0.00USD-100.000%(-6.77)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 6, 2022

07:00AM EST Now Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib GlobeNewswire Inc

Dec 23, 2021

10:35AM EST Low-Volume Stock Cyclacel Shares Tick Higher Following National Institutes Of Health ClinicalTrials.gov Listing For Co.'s 'Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome,' Shows Recruiting Benzinga

07:00AM EST Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 GlobeNewswire Inc

Nov 10, 2021

06:08PM EST Cyclacel Pharmaceuticals Q3 EPS $(0.54) Beats $(0.65) Estimate Benzinga

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

Nov 5, 2021

09:46AM EDT Cyclacel Announces Dosing Of First Patient In Phase 1/2 Study Of Oral Fadraciclib In Patients With Leukemias Or Myelodysplastic Syndromes Benzinga

09:42AM EDT Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced dosing of the first patient in the Companys multi-cohort Phase 1/2 study of oral fadraciclib in patients with leukemias or myelodysplastic syndromes (MDS). GlobeNewswire Inc

Oct 29, 2021

07:00AM EDT Cyclacel Pharmaceuticals to Release Third Quarter 2021 Financial GlobeNewswire Inc

Sep 8, 2021

07:00AM EDT Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in three investor conferences in September. GlobeNewswire Inc

Aug 11, 2021

04:50PM EDT Cyclacel Pharmaceuticals Q2 EPS $(0.56) Misses $(0.50) Estimate Benzinga

04:05PM EDT - Announces First Patients with Solid Tumors Dosed with Oral Fadraciclib -- Additional Phase 1/2 Trials for Fadraciclib and CYC140 Expected to Follow -- Cash Runway to Early 2023 -- Conference Call Scheduled August 11, 2021 at 4:30 p.m. ET - GlobeNewswire Inc

09:06AM EDT Earnings Scheduled For August 11, 2021 Benzinga

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

04:27AM EDT Earnings Scheduled For August 11, 2021 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 3, 2021

07:00AM EDT Cyclacel Pharmaceuticals to Release Second Quarter 2021 Financial GlobeNewswire Inc

Jul 13, 2021

08:05AM EDT The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data Benzinga

07:28AM EDT Cyclacel Doses First Patient In Phase 1/2 Study Of Oral Fadraciclib In Advanced Solid Tumors And Aggressive Lymphomas RTTNews

07:05AM EDT Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Advanced Solid Tumors and Aggressive Lymphomas Benzinga

07:01AM EDT Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced dosing of the first patient in the Companys multi-cohort Phase 1/2 study of oral fadraciclib in patients with advanced solid tumors. GlobeNewswire Inc

Jul 7, 2021

07:16AM EDT Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann's Virtual 2021 Healthcare Conference Benzinga

07:15AM EDT Cyclacel Pharmaceuticals to Present at Ladenburg GlobeNewswire Inc

Jun 17, 2021

04:14PM EDT Cyclacel Pharmaceuticals Approves Renewal Of Employment Of CEO And COO Benzinga

May 12, 2021

04:20PM EDT Cyclacel Pharmaceuticals Q1 EPS $(0.50) Misses $(0.49) Estimate Benzinga

04:05PM EDT - Announces IND Authorization by FDA for Fadraciclib, a CDK2/9 Inhibitor, in Solid Tumors -- Recent Publication Reported that Overactive KRAS Mutants are Impeded by CDK9 Inhibition -- Following Recent Financing, Cash Runway Extended to Early 2023 -- Conference Call Scheduled May 12, 2021 at 4:30 p.m. ET - GlobeNewswire Inc

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

04:22AM EDT Earnings Scheduled For May 12, 2021 Benzinga

May 5, 2021

07:00AM EDT Cyclacel Pharmaceuticals to Release First Quarter 2021 Financial GlobeNewswire Inc

Apr 30, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 30, 2021 Benzinga

06:38AM EDT Oppenheimer Initiates Coverage On Cyclacel Pharmaceuticals with Outperform Rating, Announces Price Target of $17 Benzinga

Apr 29, 2021

04:15PM EDT Cyclacel Pharma Files Proxy Materials Benzinga

Mar 16, 2021

04:05PM EDT Cyclacel Pharmaceuticals Announces Closing of $14.5 Million GlobeNewswire Inc

Mar 15, 2021

07:18AM EDT Cyclacel To Present At Oppenheimer 31st Annual Healthcare Conference Mar. 18 At 9:20 a.m. ET Benzinga

07:16AM EDT Cyclacel to Present at the Oppenheimer 31st Annual Healthcare GlobeNewswire Inc

Mar 12, 2021

11:50AM EST Cyclacel Pharmaceuticals Presses Capital Raise Button Benzinga

09:59AM EST Cyclacel Pharma Prices Underwritten Public Offering Of 1.81 Mln Shares At $7.00/shr RTTNews

08:33AM EST Cyclacel Pharmaceuticals Prices 1,807,143 Share Common Stock Offering At $7/Share Benzinga

08:30AM EST Cyclacel Pharmaceuticals Prices $12.65 Million Underwritten Public GlobeNewswire Inc

07:36AM EST The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs Benzinga

Mar 11, 2021

04:01PM EST Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock; No Terms Disclosed Benzinga

04:01PM EST Cyclacel Pharmaceuticals Announces Proposed Public Offering of GlobeNewswire Inc

03:38PM EST Exclusive: Greenwich LifeSciences CEO Calls Stock's Meteoric Rise 'Very Emotional' Benzinga

Feb 25, 2021

04:50PM EST Cyclacel Pharmaceuticals Q4 EPS $(1.34) Misses $(0.51) Estimate Benzinga

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 23, 2021

03:57PM EST USPTO Site Shows Cyclacel Pharmaceuticals Patent For 'Process for preparing purine derivatives' Benzinga

Feb 19, 2021

07:00AM EST Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year GlobeNewswire Inc

Feb 10, 2021

07:00AM EST Cyclacel Pharmaceuticals Announces Presentation at 2021 BIO CEO & GlobeNewswire Inc

Jan 11, 2021

07:53AM EST Cyclacel Pharmaceuticals Announces Key Business Objectives For 2021 Benzinga

07:46AM EST Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures GlobeNewswire Inc

Dec 30, 2020

07:00AM EST Cyclacel Pharmaceuticals to Present at Biotech GlobeNewswire Inc

Dec 22, 2020

08:08AM EST Cyclacel Pharmaceuticals Announces At-The-Market $7M Investment By Fundamental Investor Acorn Bioventures Benzinga

08:00AM EST - Strategic investment from single biotech-focused institutional investor - GlobeNewswire Inc

Dec 21, 2020

07:17AM EST Cyclacel Pharma Announces Election Of Brian Schwartz To Board RTTNews

07:00AM EST Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election ofBrian Schwartz, M.D., to its Board of Directors. GlobeNewswire Inc

Nov 11, 2020

04:09PM EST Cyclacel Pharmaceuticals Q3 EPS $(0.47) Beats $(0.55) Estimate Benzinga

04:05PM EST Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the third quarter 2020 and certain business highlights. GlobeNewswire Inc

07:38AM EST The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap Benzinga

04:09AM EST Earnings Scheduled For November 11, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Oct 29, 2020

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

Oct 26, 2020

10:14AM EDT Cyclacel Pharmaceuticals shares are trading higher after the company's Phase 1 trial for cancer treatment showed positive results. Benzinga

08:28AM EDT Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity, Good Oral Bioavailability Of Fadraciclib In Patients With Advanced Solid Tumors At EORTC-NCI-AACR Symposium 2020 Benzinga

08:26AM EDT Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor GlobeNewswire Inc

Oct 23, 2020

04:32PM EDT Cyclacel Pharmaceuticals Announces That It Appointed Mark Kirschbaum As Chief Medical Officer Benzinga

04:30PM EDT Cyclacel Pharmaceuticals Announces Appointment of Mark Kirschbaum, GlobeNewswire Inc

Oct 5, 2020

07:00AM EDT Cyclacel Pharmaceuticals to Present at the October 2020 Lytham GlobeNewswire Inc

Sep 21, 2020

07:10AM EDT Cyclacel Announces Fadraciclib Abstract Selected For Oral Presentation At The 32nd EORTC-NCI-AACR Symposium 2020 RTTNews

07:08AM EDT Cyclacel Announces Fadraciclib Abstract Selected For Oral Presentation In The Late Breaking And Best Proffered Paper Session At 32nd EORTC-NCI-AACR Symposium 2020 Sat. Oct. 24 Benzinga

07:00AM EDT Cyclacel Announces Fadraciclib Abstract Selected for Oral GlobeNewswire Inc

Aug 13, 2020

08:18AM EDT The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller Benzinga

Aug 12, 2020

04:21PM EDT Cyclacel Pharmaceuticals Q2 EPS $(0.58) Misses $(0.47) Estimate Benzinga

04:06PM EDT Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the second quarter 2020 and business highlights, including an update on its progress with fadraciclib, Cyclacel's novel CDK2/9 inhibitor. GlobeNewswire Inc

04:21AM EDT Earnings Scheduled For August 12, 2020 Benzinga

Aug 5, 2020

07:01AM EDT Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial GlobeNewswire Inc

Jul 13, 2020

07:06AM EDT Cyclacel's Highlights Publication Of Peer-Reviewed Study Of Clinical Stage CDK2/9 Inhibitor Fadraciclib Benzinga

07:00AM EDT -- Characterization of fadraciclib published in peer-reviewed journal shows specificity against GlobeNewswire Inc

Share